Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Brain function

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44379   clinical trials with a EudraCT protocol, of which   7391   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,112 result(s) found for: Brain function. Displaying page 4 of 56.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-000981-41 Sponsor Protocol Number: TUXEDO-1 Start Date*: 2020-06-26
    Sponsor Name:Med. Univ. Wien, Klinik f. Innere Mdizin I, Onkologie
    Full Title: Phase II Study of Trastuzumab-Deruxtecan (T-DX; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain Metastases
    Medical condition: HER2-positive Breast Cancer with newly diagnosed or progressing Brain Metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001235-20 Sponsor Protocol Number: 14.0189 Start Date*: 2015-06-05
    Sponsor Name:St George's University of London
    Full Title: Perfusion by Arterial Spin labelling following Single dose Tadalafil In Small vessel disease
    Medical condition: PARTICIPANTS WITH EVIDENCE OF CEREBRAL SMALL VESSEL DISEASE
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001436-35 Sponsor Protocol Number: COFITAGE2016 Start Date*: 2017-01-06
    Sponsor Name:Service of Neurology, CHU Liege
    Full Title: How sleep and circadian rhythmicity promote cognitive fitness and protect against cognitive decline in the elderly population
    Medical condition: Healthy middle aged (50 - 70 y.o.) individual with and without preclinical Alzheimer's disease defined by biomarkers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004018-33 Sponsor Protocol Number: PrefrontalCircuits Start Date*: 2020-08-24
    Sponsor Name:Department of Psychiatry and Psychotherapy, Medical University of Vienna
    Full Title: Prefrontal circuits for cognitive flexibility in an extradimensional set-shifting task for humans.
    Medical condition: Major depressive disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004520-10 Sponsor Protocol Number: ACNS1021 Start Date*: 2019-06-25
    Sponsor Name:National Cancer Institute (NCI)
    Full Title: 2018-004520-10
    Medical condition: Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-003664-25 Sponsor Protocol Number: 11323 Start Date*: 2023-12-21
    Sponsor Name:University Medical Center Groningen
    Full Title: The impact of gender differences in P-glycoprotein function measured with [18F]MC225 and PET
    Medical condition: Gender, healthy volunteers
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001045-12 Sponsor Protocol Number: NO21125 Start Date*: 2016-07-20
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: A Phase II Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas.
    Medical condition: Intrinsic Brainstem Glioma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-003557-21 Sponsor Protocol Number: LixiBrain01 Start Date*: 2019-02-06
    Sponsor Name:University Hospital Tuebingen
    Full Title: Effect of insulin glargine and lixisenatide versus insulin glargine on brain insulin sensitivity in patients with type 2 diabetes
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002805-23 Sponsor Protocol Number: IFCT-1804 Start Date*: 2020-01-07
    Sponsor Name:IFCT
    Full Title: A Phase II, multi-centre study, to evaluate the efficacy and safety of osimertinib treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC) with Brain or Leptomeningeal metasta...
    Medical condition: EGFR-mutated Non-small cell lung cancer (NSCLC) with Brain or Leptomeningeal metastases
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    22.0 10018065 - General disorders and administration site conditions 10071975 EGFR gene mutation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000875-34 Sponsor Protocol Number: MM1807 Start Date*: 2018-05-30
    Sponsor Name:National Center for Cancer Immune Therapy
    Full Title: Efficacy of immunotherapy in melanoma patients with brain metastases treated with steroids
    Medical condition: Metastatic melanoma with brain metastasis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006011-74 Sponsor Protocol Number: BI-Brain-01 Start Date*: 2007-02-01
    Sponsor Name:Rigshospitalet
    Full Title: A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy
    Medical condition: Primary malignant brain tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-000992-18 Sponsor Protocol Number: 12-016 Start Date*: 2014-09-26
    Sponsor Name:UMC Utrecht
    Full Title: Proactive versus reactive inhibition in ADHD: Genetics, neurobiology and pharmacology
    Medical condition: Attention-Deficit Hyperactivity Disorder (ADHD)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004414-10 Sponsor Protocol Number: TERIFL08519 Start Date*: 2018-02-23
    Sponsor Name:MS Centrum, Department of Neurology, Sshlgrenska University Hospital
    Full Title: Determination of the concentration of Teriflunomide in serum and cerebrospinal fluid from patients with multiple sclerosis who are treated with Teriflunomide 14 mg daily.
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004614-10 Sponsor Protocol Number: CA209-429 Start Date*: 2017-06-12
    Sponsor Name:University Hospital Tübingen
    Full Title: An open label phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and nivolumab in patients with four and more symptomatic brain metastases of melanoma
    Medical condition: Patients with stage IV melanoma and four or more symptomatic brain metastases, who are not eligible for surgery or radiosurgery
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025655 Malignant melanoma of skin LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006128 Brain metastases LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000425-27 Sponsor Protocol Number: GECP21/02 Start Date*: 2021-10-08
    Sponsor Name:Fundación GECP
    Full Title: Nivolumab plus Ipilimumab plus two cycles of platinum-based chemotherapy as first line treatment for stage IV/recurrent non-small cell lung cancer (NSCLC) patients with synchronous Brain metastases
    Medical condition: Non-small cell lung cancer with brain metastasis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004290-84 Sponsor Protocol Number: tau-PET/BBRC2019 Start Date*: 2020-04-29
    Sponsor Name:BarcelonaBeta Brain Research Center
    Full Title: Characterization of cerebral tau aggregates with 18F-RO6958948 PET in the ALFA population.
    Medical condition: Alzheimer's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000758-37 Sponsor Protocol Number: NO18517 Start Date*: 2016-08-23
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas
    Medical condition: High Grade Glioma Brainstem Glioma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-017925-20 Sponsor Protocol Number: RR08/8789 Start Date*: 2010-09-07
    Sponsor Name:University of Leeds
    Full Title: Does Cocareldopa treatment in combination with routine NHS occupational and physical therapy, delivered early after stroke within a stroke service, improve functional recovery including walking and...
    Medical condition: Ischaemic or Haemorrhagic Stroke
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    14.1 10029205 - Nervous system disorders 10019016 Haemorrhagic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005738-23 Sponsor Protocol Number: CBAF312X2207 Start Date*: 2018-06-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II, patient and investigator-blinded, randomized, placebo-controlled study to evaluate efficacy, safety and tolerability of BAF312 in patients with stroke due to intracerebral hemorrhage (ICH)
    Medical condition: Intracerebral Hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10022754 Intracerebral hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016080-11 Sponsor Protocol Number: DIPGstudyVUmc01 Start Date*: 2011-02-25
    Sponsor Name:VU University Medical Center
    Full Title: A COMPREHENSIVE AND TARGETED THERAPY APPROACH IN PEDIATRIC MALIGNANT PONTINE GLIOMAS
    Medical condition: Pediatric malignant pontine gliomas
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006143 Brain stem glioma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Feb 08 13:40:40 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA